Uveitis Disease - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035

Uveitis Disease Market Outlook

Thelansis's "Uveitis Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uveitis Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Uveitis Disease Overview

Uveitis is a heterogeneous group of intraocular inflammatory disorders affecting the uveal tract, including the iris, ciliary body, and choroid, and is classified anatomically as anterior, intermediate, posterior, or panuveitis. The disease may result from infectious causes such as herpesviruses, tuberculosis, toxoplasmosis, and syphilis, or from non-infectious immune-mediated mechanisms frequently associated with systemic autoimmune disorders including Behcet disease, sarcoidosis, juvenile idiopathic arthritis, and spondyloarthropathies. Clinical presentation varies by anatomical involvement and commonly includes eye pain, redness, photophobia, blurred vision, and floaters.

Chronic or inadequately controlled uveitis can lead to severe vision-threatening complications including cataract, glaucoma, cystoid macular edema, and retinal damage. Diagnosis involves comprehensive ophthalmic examination supported by imaging techniques such as optical coherence tomography and fluorescein angiography, alongside targeted systemic investigations to identify underlying infectious or autoimmune etiologies.

Corticosteroids remain the cornerstone of treatment for non-infectious uveitis and may be administered topically, periocularly, or systemically depending on disease severity and location. Immunosuppressive therapies including methotrexate, azathioprine, and mycophenolate are commonly used in chronic or recurrent disease, while biologics such as adalimumab are increasingly utilized in refractory non-infectious uveitis. Despite therapeutic advances, recurrent inflammation, long-term corticosteroid toxicity, and risk of irreversible visual impairment continue to represent major unmet clinical challenges.

Key Highlights

• In China, total prevalent uveitis cases are projected to increase from approximately 3,611,621 in 2025 to nearly 3,754,973 by 2035, reflecting a growing disease burden.
• Anterior uveitis remains the most common clinical subtype across diagnosed patient populations.
• Chronic and recurrent inflammation continues to contribute significantly to long-term visual impairment and reduced quality of life.
• Increasing use of immunosuppressive therapies and biologics is improving disease control in refractory non-infectious uveitis.
• Early diagnosis and multidisciplinary disease management remain critical to preventing irreversible ocular complications.

Market Overview

• The China uveitis market is projected to grow from approximately $80.70 MN in 2025 to nearly $97.30 MN by 2035, reflecting moderate market expansion.
• Market growth is supported by:
• Increasing adoption of biologics and steroid-sparing immunomodulatory therapies
• Improved diagnosis and long-term management of chronic and recurrent disease
• Market value growth is driven by rising treatment duration and increasing utilization of advanced ophthalmic therapies.
• Future market growth will depend on development of targeted immunotherapies, safer long-term treatment strategies, and improved management of refractory uveitis.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Priovant Therapeutics, Inc.
• Changchun GeneScience Pharmaceutical Co., Ltd.
• Eli Lilly and Company